Novo Nordisk, Lumen Bioscience Collaborate For Oral Biologics For Cardiometabolic Diseases

by Vandana Singh, Benzinga Editor

June 16, 2021 9:30 AM | 1 min read | Make a Comment

Privately-held Lumen Bioscience has entered into a research collaboration with Novo Nordisk A/S NVO to evaluate the use of Lumen's spirulina-based drug development and manufacturing platform in Novo Nordisk's R&D activities within obesity and other metabolic disorders.
The initial stages of the research collaboration will take place over approximately one year.
Lumen and Novo Nordisk will jointly develop and evaluate the bioactivity of metabolically relevant molecules produced and delivered using spirulina.
Financial terms were not disclosed.
Price Action: NVO shares are down 0.20% at $84.40 during the market session on the last check Wednesday.

Posted In: Biotech News Health Care Contracts General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.